Active, Not Recruiting
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
NCT05194293
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
- Medical College of Wisconsin Milwaukee, Wisconsin, United States